Developing Therapies that Change People's Lives

WICH 2017

It is our privilege to announce that the Johns Hopkins University will be hosting the 6th World Intracranial Hemorrhage Conference (WICH 2017) on May 1-3, 2017 in Baltimore, Maryland, United States. The Conference will feature highly respected speakers who will share, discuss, debate and dissect significant new developments and scientific advancements that will impact the future of intracranial hemorrhage. The planned program will provide learning opportunities for students​, medical specialists and clinicians from all fields of endeavor, as well as world-class content for researchers and industry supporters.

The main theme of the conference is "Accelerating Scientific Discoveries and Major Milestones in Intracranial Hemorrhage Therapeutics." The conference will lay a platform for the interaction between experts around the world and aims to encourage further research via the exchange of ideas between researchers and clinicians. The program will include all fields of intracranial hemorrhage, in order to understand the mechanisms behind these varied conditions and discuss how to improve their treatments.

Please click on the picture to be directed to the World ICH 2017 website.

Brain Injury Outcomes

Johns Hopkins University
1550 Orleans Street
CRB-II, 3M50 South
Baltimore, MD 21231 USA
Office:   (410) 614-6996
Fax: (410) 502-7869
 
24-Hr: (410) 736-1368

Our Latest Clinical Trials

  • All
  • Active
  • Complete
  • Dizziness
  • Epilepsy
  • Stroke
  • Default
  • Title
  • Date
  • Random
  • MISTIE-III is a 500-patient, international multicenter clinical trial launched in 2013 to confirm the safety and long-term efficacy of thrombolysis in the treatment of intracerebral hemorrhage (ICH). The 5-year trial is funded by NINDS and was launched in Nov 2013. Up to 100 of the top stroke centers across the world are expected to participate in this 5-year project.
    Read More
    • Active
    • Stroke
  • CLEAR-III was an international 500-patient randomized clinical trial evaluating thrombolysis vs. medical management alone in the treatment of intraventricular hemorrhage. Enrollment in this ground-breaking trial completed in Jan-2015. Final results are expected in 2016.
    Read More
    • Complete
    • Stroke
  • IVH Therapeutics is a clinical registry running on a mobile app to track worldwide adoption of the therapy and techniques that were evaluated during the CLEAR III clinical trial. It is hoped that this registry will help stroke researchers and scientists gain valuable information about the use of intraventricular thrombolytic therapy as it is generalized to community hospitals and specialized stroke centers around the world, many of which may not have participated in the clinical trial.
    Read More
    • Active
    • Stroke
  • The NEWTON (Nimodipine microparticles to Enhance recovery While reducing TOxicity after subarachNoid hemorrhage) study is a multicenter, randomized, controlled, clinical trial evaluating Edge Therapeutics' novel formulation, EG-1962, compared to the current standard of care, oral nimodipine, to treat patients that have suffered an aneurysmal subarachnoid hemorrhage (aSAH) from a ruptured brain aneurysm.
    Read More
  • AVERT is a randomized multicenter clinical trial evaluating video-oculography (VOG), nystagmography and audiometry in patients presenting to an emergency department with dizziness and vertigo. The goal is a better treatment pathway with fewer misdiagnoses.
    Read More
    • Active
    • Dizziness
    • Stroke
  • HU Prevent is a multicenter placebo-controlled clinical trial of hydroxyurea in children with sickle cell disease. The goal is to determine if hydroxyurea can prevent brain injury and stroke. BIOS is the national coordinating center for this trial conducted at 25 clinical sites.
    Read More
    • Active
    • Stroke
  • EQUIGEN was comprised of two bioequivalency trials. The EQUIGEN Chronic Dose trial compared two disparate generics of lamotrigine. The EQUIGEN Single Dose trial compared branded lamotrigine with two disparate generics of lamotrigine for patients with epilepsy. BIOS served as the Coordinating Center for both trials.
    Read More
    • Complete
    • Epilepsy
  • DIAS-4 is a phase III study, sponsored by Lundbeck, to evaluate the efficacy and safety of desmoteplase in study participants with acute ischemic stroke. It is a follow-on to the DIAS-3 study which completed in March-2014. BIOS (Brain Injury Outcomes Clinical Trial Coordinating Center) is acting as a local coordinating team for this study at Johns Hopkins.
    Read More
    • Active
    • Stroke
  • MISTIE-II was a phase-II clinical trial across 32 clinical sites evaluating efficacy and long-term outcomes of thrombolysis in intracerebral hemorrhage (ICH). Results were presented at the 2013 International Stroke Conference.
    Read More
    • Complete
    • Stroke
  • ICES was the third tier in the MISTIE phase-II clinical trial. ICES evaluated minimally-invasive endoscopic removal of the intracerebral hematoma as a faster alternative to catheter-delivered intermittent thrombolytic therapy. The last patient completed in 2013. Publication of final results is forthcoming. Meanwhile, plans are underway for the next phase of this program.
    Read More
    • Complete
    • Stroke
  • CLEAR-IVH was a phase-II international trial enrolling 52 patients from 20 sites. It was completed in 2008. This study provided an early demonstration that treatment of IVH with catheter-delivered low-dose tPA can be safe and holds promise as a potential new therapy for intraventricular hemorrhage (IVH), a devastating form of hemorrhagic stroke.
    Read More
    • Complete
    • Stroke
  • SMARTS is a study conducted by Dr. John Krakauer exploring how the brain changes over the first year following a stroke. We are using several non-invasive techniques, including MRI, transcranial magnetic stimulation and measures of arm movement to learn more about how individuals recover from stroke.
    Read More
    • Active
    • Stroke
  • POINT is a randomized, double-blind, multicenter clinical trial to determine whether clopidogrel (Plavix®) is effective in preventing major ischemic vascular events such as ischemic stroke and myocardial infarction in newly-diagnosed patients with TIA and minor ischemic stroke. BIOS is providing local coordination for the Johns Hopkins site.
    Read More
    • Active
    • Stroke